retatrutide vs cagrisema The future of weight loss is moving beyond just eating less and entering the era of powerful metabolic signaling. Here is a breakdown of the 2026 pipeline featured in the infographic. Semaglutide. Tirzepatide. Retatrutide. Same goal

Currently, orforglipron has not been approved for use in the UK, but approval for use in the US has been granted so its likely

But for researchers who want to maintain some metabolic support during a GLP-1 drug holiday, peptide stacking offers potential options

GLP-1 receptors have been identified in bone mesenchymal stem cells, indicating a broader physiological role for these incretin hormones

Tirzepatide microdosing: Smaller incremental doses Strategy B: Increased frequency with smaller doses This involves administering a very small dose more frequently than once a week (for example, every 3-4 days) to keep drug levels more stable and avoid the sharp peak that can cause side effects

Individual ingredients have published research, but no OTC finished product has been shown in a peer-reviewed trial to replicate the 7-24% body weight loss that prescription GLP-1 receptor agonists produce